Summary & Overview
HCPCS C9071: Injection, Viltolarsen 10 mg
HCPCS Level II code C9071 denotes a 10 mg injection unit of viltolarsen, an intravenously or intramuscularly administered drug used in specialized treatment protocols. Nationally, accurate coding for high-cost specialty injectables like viltolarsen is critical for claims processing, utilization tracking, and payer coverage determinations. The code facilitates standardized billing for each 10 mg unit of drug supplied and helps payers and providers reconcile dosing and reimbursement.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage considerations, common billing modifiers, and clinical context for use of viltolarsen in outpatient infusion and specialty clinic settings. The publication outlines how HCPCS Level II code C9071 is used to report the drug product unit, typical places of service, and the implications for billing workflows.
This summary provides guidance on what to expect in payer policies, benchmarking topics, and administrative issues relevant to viltolarsen injections. It highlights the elements clinicians and billing teams should verify on claims (such as units reported and site of service) and flags where additional documentation or prior authorization processes are commonly required. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code C9071 represents Injection, viltolarsen, 10 mg. This code denotes the administration of a 10 mg unit of viltolarsen, a medication typically provided by injection. The service type is drug administration and the typical site of service is an outpatient infusion/ambulatory clinic or specialty infusion center, where injectable disease-modifying therapies are commonly delivered.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related procedure codes.
Clinical & Coding Specifications
Clinical Context
A typical patient is a male child or adolescent diagnosed with Duchenne muscular dystrophy (DMD) who is eligible for exon-skipping therapy with viltolarsen. The medication C9071 represents a 10 mg vial of viltolarsen for intravenous infusion. Clinical workflow: the patient presents to an outpatient infusion center or hospital outpatient department for scheduled dosing (weight-based dosing determined by clinician). Pre-infusion assessment includes verification of identity, review of recent weight, vital signs, medication reconciliation, allergy check, and confirmation of prior treatment tolerance. An infusion nurse or pharmacist reconstitutes and prepares the prescribed dose under sterile technique, completes drug verification and infusion pump setup, and documents lot number and expiration. The infusion is administered via peripheral IV or established central access over the recommended infusion time while monitoring for infusion reactions. Post-infusion observation ensures hemodynamic stability and absence of adverse effects; documentation includes route, dose (mg), vial count (C9071 units), lot numbers, and time. Typical sites of service are outpatient infusion centers, hospital outpatient departments, and occasionally ambulatory infusion suites. Billing uses the HCPCS Level II code C9071 per 10 mg increment, with applicable modifiers to indicate specific circumstances such as unusual procedural services, bilateral procedures, or services requiring a distinct professional or technical component. Payors commonly involved include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare for coverage determination and prior authorization requirements.
Coding Specifications
| Modifier | Description |
|---|